What does Spinogenix do?

Spinogenix, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles. Founded by Dr. Stella Sarraf, the company is dedicated to developing small molecule therapeutics aimed at restoring synapses to treat various neurodegenerative, neuropsychiatric, and neurodevelopmental diseases, including Alzheimer’s disease, ALS, schizophrenia, glaucoma, and Fragile X syndrome. Spinogenix focuses on regenerative therapies that not only slow disease progression but also aim to reverse synaptic loss. Their lead candidate, Tazbentetol, is currently in Phase 2 trials and has shown promising cognitive improvements in Alzheimer’s patients. The company utilizes its proprietary TAGS™ platform to develop orally administered small molecules, which facilitate easier administration and better central nervous system penetration. Spinogenix is privately held and supported by various investors, including NIH and DoD grants, and is actively expanding its research programs.